%0 Journal Article
%T Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry
%A Radzislaw Kordek
%A Piotr Potemski
%A Renata Kusinska
%A Elzbieta Pluciennik
%A Andrzej Bednarek
%J Journal of Experimental & Clinical Cancer Research
%D 2010
%I BioMed Central
%R 10.1186/1756-9966-29-39
%X Despite the method of dichotomization and statistical analysis, there were cases with discordant results comparing immunohistochemistry and RT-PCR analysis. For dichotomisation based on quartiles and ROC, 14% of cases were negative on immunohistochemical examination for CK5/6, but presented high CK5 mRNA levels. There were also 48-55% cases, which were CK5/6-immunopositive, but were negative by mRNA examination. Similar discordances were observed for CK14 and CK17.Basal keratin mRNAs did not correlate with ER mRNA levels, while immunohistochemistry produced significant relationship with ER status.Our observation suggest that both method may produce different results in a small proportion of cases. Discordance between immunohistochemistry and RT-PCR may confound attempts to establish a simple methods for identification of basal-like tumors.Heterogeneity of breast cancer at the molecular level was supported by data from cDNA microarrays [1,2]. Tumors lacking ER form three groups: a basal-like subtype, HER2-positive subtype, and a normal breast-like subtype. Basal-like subtype is characterized by multigenetic signature, usually with high expression of high molecular weight cytokeratins normally expressed in basal myoepithelial cells: keratin 5 (CK5), 14 (CK14) and keratin 17 (CK17) [1,2]. They usually express vimentin and p-cadherin, and more than 60% of them also express epidermal growth factor receptor (EGFR) [3,4].A great interest in basal like-cancers produced attempts to determine basal-like tumors by the use of a much more easier technique such as immunohistochemistry. Unfortunately, both methods -- oligonucleotide microarrays and immunohistochemistry - do not produce identical results. In the study by Nielsen and al., immunohistochemical panel for basal-like cancers was defined as lack of ER and HER2 expression and positivity for CK5/6 or EGFR [5]. Unfortunately, this panel still presented only 76% sensitivity for basal-like tumors derived from a microarray stud
%U http://www.jeccr.com/content/29/1/39